Suppr超能文献

相似文献

1
Astrocytes and therapeutics for Parkinson's disease.
Neurotherapeutics. 2010 Oct;7(4):413-23. doi: 10.1016/j.nurt.2010.07.001.
2
Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease.
Curr Pharm Des. 2017;23(33):4936-4947. doi: 10.2174/1381612823666170710163731.
3
Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's Disease.
Curr Med Chem. 2016;23(7):686-700. doi: 10.2174/0929867323666160122115057.
4
[Anti-oxidants in astrocytes as target of neuroprotection for Parkinson's disease].
Nihon Yakurigaku Zasshi. 2021;156(1):14-20. doi: 10.1254/fpj.20071.
5
Neuroprotective effects of zonisamide target astrocyte.
Ann Neurol. 2010 Feb;67(2):239-49. doi: 10.1002/ana.21885.
7
Astrocytes in Parkinson's disease: from preclinical assays to in vivo imaging and therapeutic probes.
Neurobiol Aging. 2020 Nov;95:264-270. doi: 10.1016/j.neurobiolaging.2020.07.012. Epub 2020 Jul 21.
8
Neuroprotective strategies in Parkinson's disease : an update on progress.
CNS Drugs. 2003;17(10):729-62. doi: 10.2165/00023210-200317100-00004.
10
Astrocytes: From the Physiology to the Disease.
Curr Alzheimer Res. 2019;16(8):675-698. doi: 10.2174/1567205016666190830110152.

引用本文的文献

1
Ca waves in astrocytes: computational modeling and experimental data.
Front Cell Neurosci. 2025 Mar 28;19:1536096. doi: 10.3389/fncel.2025.1536096. eCollection 2025.
2
Astrocytes-associated research in Parkinson's disease: an explored trends analysis.
Front Aging Neurosci. 2025 Mar 27;17:1563142. doi: 10.3389/fnagi.2025.1563142. eCollection 2025.
5
Inflammation and heterogeneity in synucleinopathies.
Front Immunol. 2024 Aug 30;15:1432342. doi: 10.3389/fimmu.2024.1432342. eCollection 2024.
6
A Review on Therapeutic Strategies against Parkinson's Disease: Current Trends and Future Perspectives.
Mini Rev Med Chem. 2025;25(2):96-111. doi: 10.2174/0113895575303788240606054620.
7
Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.
PLoS One. 2023 Sep 21;18(9):e0291927. doi: 10.1371/journal.pone.0291927. eCollection 2023.
9
Dysfunction of the neurovascular unit in brain aging.
J Biomed Res. 2023 Apr 15;37(3):153-165. doi: 10.7555/JBR.36.20220105.

本文引用的文献

1
Genetic animal models of Parkinson's disease.
Neuron. 2010 Jun 10;66(5):646-61. doi: 10.1016/j.neuron.2010.04.034.
2
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.
J Biol Chem. 2010 Mar 19;285(12):9262-72. doi: 10.1074/jbc.M109.081125. Epub 2010 Jan 13.
3
Well-water consumption and Parkinson's disease in rural California.
Environ Health Perspect. 2009 Dec;117(12):1912-8. doi: 10.1289/ehp.0900852. Epub 2009 Jul 31.
4
Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons.
J Neurosci. 2009 Dec 16;29(50):15923-32. doi: 10.1523/JNEUROSCI.3910-09.2009.
5
Neuroglia in neurodegeneration.
Brain Res Rev. 2010 May;63(1-2):189-211. doi: 10.1016/j.brainresrev.2009.11.004. Epub 2009 Nov 26.
6
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.
Expert Opin Investig Drugs. 2009 Nov;18(11):1619-31. doi: 10.1517/13543780903241615.
7
Adenosine signaling and function in glial cells.
Cell Death Differ. 2010 Jul;17(7):1071-82. doi: 10.1038/cdd.2009.131. Epub 2009 Sep 18.
8
Is Parkinson's disease a prion disorder?
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12571-2. doi: 10.1073/pnas.0906759106. Epub 2009 Jul 28.
9
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5. doi: 10.1073/pnas.0903691106. Epub 2009 Jul 27.
10
Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
J Neurosci. 2009 Jul 29;29(30):9651-9. doi: 10.1523/JNEUROSCI.0833-09.2009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验